Noncompliance with adjuvant radiation, chemotherapy, or hormonal therapy in breast cancer patients

Thu, Aye Moe; Barone, Julie; Wallis, Ashley E.; Wu, Nancy Jade; Garcia, L.; Estabrook, Alison; Rosenbaum-Smith, Sharon M.; Tartter, Paul Ian

doi:10.1016/j.amjsurg.2008.06.027

Cited by 102 publications

(92 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other studies support that finding 22,25,30 . At the other end of the spectrum, a study on adjuvant tamoxifen found that non-adherence (37% within the first year) was significantly associated with younger age (p < 0.001) 21 , a finding that has also been demonstrated in other studies 22,25 . Non-adherence among the elderly has been suggested to possibly be a result of psychosocial issues such as memory problems and decreased social support 22 .…”

Section: Factors Affecting Adherence To Adjuvant Endocrine Therapysupporting

confidence: 53%

“…Some patient-related factors, such as remembering to take the medication, are directly under the patient's control; others are inherent. Age has been identified as one of the key factors associated with lower adherence rates, and older age groups (>75 years) and younger age groups (<45 years) have both been significantly associated with non-adherence 3,21,22,25,29,30 . Of 961 women 65 years of age or older, 49% discontinued tamoxifen before the end of a 5-year administration period, and those who discontinued the drug were more likely to be 75 years of age 29 .…”

Section: Factors Affecting Adherence To Adjuvant Endocrine Therapymentioning

confidence: 99%

“…Other patient-related factors that have been associated with non-adherence are antidepressant use and mastectomy 21,22,25 . Depression has been noted as a risk factor for non-adherence to medications 31 .…”

Section: Factors Affecting Adherence To Adjuvant Endocrine Therapymentioning

confidence: 99%

“…Most of the reports involve tamoxifen, given its longer use (compared with ais) in this setting. In a study of 788 patient on adjuvant tamoxifen, as many as 37% either refused or stopped taking the medication within 1 year 21 . Other studies showed relatively good adherence in the first year, but a decline over time.…”

Section: Non-trial Settingsmentioning

confidence: 99%

See 3 more Smart Citations

Patient Adherence to Aromatase Inhibitor Treatment in the Adjuvant Setting

et al. 2011

View full text Add to dashboard Cite

Improvements in adjuvant systemic therapy and detection of early disease have resulted in a decline of breast cancer death rates across all patient age groups in Canada. Non-adherence to adjuvant hormonal therapy in the setting of early breast cancer may significantly affect patient outcome. Factors associated with medication adherence are complex and may be patient-related, therapy-related, and health care provider–related. To date, there is a gap in the literature concerning a comprehensive understanding of factors related to medication adherence with anti-estrogen therapy in the adjuvant setting. The literature suggests that strategies for improving adherence should focus on education of patients, assessment of the ability of patients to understand their disease and related recurrence factors, and facilitation of adherence by patients by providing adequate support and strategies for good self-management. However, more research is needed to better understand how health care providers can support women with breast cancer on oral therapy in the adjuvant setting.

show abstract

Section: Factors Affecting Adherence To Adjuvant Endocrine Therapysupporting

confidence: 53%

Section: Factors Affecting Adherence To Adjuvant Endocrine Therapymentioning

confidence: 99%

Section: Factors Affecting Adherence To Adjuvant Endocrine Therapymentioning

confidence: 99%

Section: Non-trial Settingsmentioning

confidence: 99%

See 2 more Smart Citations

Patient Adherence to Aromatase Inhibitor Treatment in the Adjuvant Setting

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Few previous studies have evaluated compliance of patients with physician recommendations for chemotherapy, and data that examine racial/ethnicity minority populations are more limited [17][18][19][20][21]. The reasons for a lack of compli- ance or underuse of adjuvant therapies are not well documented.…”

Section: Discussionmentioning

confidence: 99%

Preoperative Chemotherapy for Operable Breast Cancer Is Associated with Better Compliance with Adjuvant Therapy in Matched Stage II and IIIA Patients

et al. 2011

View full text Add to dashboard Cite

Introduction. Preoperative chemotherapy (PC) for operable breast cancer has shown significant benefits in prospective trials. Many patients are treated in the community setting and some may question the applicability of PC outside the university setting.Methods. Retrospective review was performed of stage II and IIIA breast cancer patients treated from January 2002 to July 2009. Fifty-three of 57 patients who underwent PC were matched based on age, tumor size, and hormone receptor status with 53 patients who did not undergo PC. Differences in patient compliance with physician recommendations for all types of adjuvant therapy were evaluated. Crude odds ratios and adjusted odds ratios derived from conditional logistic regression models were calculated.Results. There were 106 patients included. Patient compliance with chemotherapy was better in the PC group than in the adjuvant chemotherapy (AC) group (100% versus 70%; p ‫؍‬ .0001). Similarly, more patients

show abstract